Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083

In a large preexposure prophylaxis trial with high STI incidence, CAB-LA maintained robust protective efficacy relative to TDF/FTC in the setting of bacterial STIs.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2024-11-19
DOI
https://doi.org/10.1093/cid/ciae572
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083

Jorge A. Gallardo-Cartagena, Anne Rompalo, Jessica Amber Jennings, Carl J. Fichtenbaum et al.
Clinical Infectious Diseases
HIV/AIDS Research and Interventions
article

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083

Jorge A. Gallardo-Cartagena, Anne Rompalo, Jessica Amber Jennings, Carl J. Fichtenbaum, Juan Carlos Hinojosa Boyer, Meredith E. Clement, Edgar T. Overton, Kailazarid Gomez Feliciano, Christopher B. Hurt, Richard Novák, Breno Santos, Jessica Justman, Beatriz Gilda Jegerhorn Grinsztejn, Kenneth Hugh Mayer, Daniel Reirden, Nuntisa Chotirosniramit, Roberto C. Arduino, Shobha Swaminathan, Keren Middelkoop, Rachel M. Presti, Raphael J. Landovitz, Trần Việt Hà, Marybeth McCauley, Sharon Mannheimer, James F. Rooney, Aditya H. Gaur, Nittaya Phanuphak, Albert Liu, Mayara Secco Torres Silva, Julie Franks, Omar Sued, Roy M. Gulick, Eileen F. Dunne, Jesse L. Clark, Ian Frank, Pedro Gonzáles, Manya Magnus, Carlos del Rı́o, Temitope Oyedele, Marcelo Losso, Ryan Kofron, Colleen F. Kelley, Christopher Hall, Brett Hanscom, Alex R. Rinehart, Lydia Soto-Torres, Suwat Chariyalertsak, Cornelius van Dam, Sue Ellen Abdalian, José A. Bazan, Daniel Haines, Robinson Cabello
article en

Abstract

In a large preexposure prophylaxis trial with high STI incidence, CAB-LA maintained robust protective efficacy relative to TDF/FTC in the setting of bacterial STIs.

Clinical Infectious DiseasesVol. 82(2)
Family Health International 360 (US), Beth Israel Deaconess Medical Center (US), Harvard University (US), University of California, Los Angeles (US), Columbia University Irving Medical Center (US), National Institute of Infectious Diseases (JP), Fred Hutch Cancer Center (US), ViiV Healthcare (United Kingdom) (GB), National Institute of Allergy and Infectious Diseases (US), Statistics Collaborative (US), Gilead Sciences (United States) (US), Gilead Sciences (Australia) (AU), Fenway Health (US), Chiang Mai University (TH), Fundação Oswaldo Cruz (BR), The Ohio State University (US), Louisiana State University Health Sciences Center New Orleans (US), Columbia University (US)
Good health and well-being
Openalex Percentile: Top 73%
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.